NIH spent about $4.1 billion on cystic fibrosis research before the first approved drug, a tally finds
NIH put $3.2 billion into basic cystic fibrosis research from 1985 to 2012, an essay in The Conversation reports. Its author warns that grant policies from the Office of Management and Budget could limit similar work.
The Scientist · Science desk
NIH funded $3.2 billion of basic cystic fibrosis research from 1985 to 2012 and approximately $940 million of applied research on potential drugs over the same period. NIH funding supported more than 6,200 papers on the disease's biology.
| Figure | Value | Note | Claim |
|---|---|---|---|
| NIH basic cystic fibrosis research, 1985–2012 | US$3.2 billion | 5 | |
| NIH applied research on potential drugs, approximately | $940 million | over the same period as basic research | 6 |
| NIH-supported papers on CF biology, more than | 6,200 papers | 27 years before Kalydeco's approval | 4 |
What happened
- Over the 27 years leading up to Kalydeco's 2012 approval, NIH funding supported more than 6,200 published studies of cystic fibrosis biology.
- The Cystic Fibrosis Foundation put in at least $200 million toward discovering or developing the drugs, and Vertex's own spending is undisclosed.
- Vertex followed Kalydeco in 2012 with Orkambi in 2015, Symdeko in 2018, Trikafta in 2019 and Alyftrek in 2024.
- The policies at issue, first proposed by the Office of Management and Budget, would increase political control over grants, limit peer review and curtail research on certain topics.
- Congress blocked those policies temporarily, and several agencies, NIH among them, still pursue portions of the agenda.
Why it matters
- exposure Peer-review limits and topic restrictions would apply to the basic genetics and biology work that the author says had to precede any drug search.
- constraint With Vertex's spending undisclosed, the public share of total spending cannot be computed, so no one can size what a cut would remove from a future drug.
- contradiction The essay's evidence and its warning part ways: the tally covers past spending, while the claim that the rules could cut off future advances is the author's inference.
The tally splits NIH money into two kinds. For 1985 to 2012 the team identified $3.2 billion for basic cystic fibrosis research and approximately $940 million for applied research on potential drugs [5][6]. Together that is about $4.14 billion [15]. The papers it paid for include celebrated milestones in understanding CFTR, the gene that causes the disease, along with studies needed to replicate, refute or refine those advances [13].
Set against the Cystic Fibrosis Foundation's investment of at least $200 million [7], NIH's identified total is about 21 times larger [17]. The Foundation's figure is a floor, so 21 is a ceiling on the ratio.
The tally shows that NIH money was present while the biology was worked out, and it leaves open whether the drugs would have failed without it. The author, who trained as a pediatrician in the late 1970s [14], argues from order of events: the genetics and biology of the disease had to be understood before anyone could begin searching for drugs, and NIH was the largest contributor to that work [8]. We think the sequence argument holds for the past.
The forward claim depends on how long drug development takes. The author says approved drugs typically rest on 20 to 30 years of basic research and eight to nine years of human testing [11]. If those phases ran back to back, that is 28 to 39 years from first basic work to approval [16]. A grant rule applied today would reach approvals decades from now, and we'd expect any effect to be hard to separate from everything else that changed in that time.
The essay's two survival figures also differ in kind. The median age of death from cystic fibrosis in 1979 was 15 [1]. The median survival age the author gives for a child born today is 66 [3]. One is an age at death and the other is an expectation for a child who has not yet lived it, so the difference between them is an estimate.
Mary Vought, the former wife of Office of Management and Budget director Russell Vought, said their daughter, who was diagnosed with cystic fibrosis, "can live likely a full life because of this miracle drug" [10]. The author wrote: "Cystic fibrosis treatments are not miracles; they required decades of research funded by a combination of public and private investments" [12].
The Cystic Fibrosis Foundation made the funding point in a 2025 letter to Russell Vought and other administration leaders, writing that "ensuring that the National Institutes of Health (NIH) is fully functional is critical for furthering our knowledge of the biology of CF and advancing CF therapeutic development" [9].
What to watch
- Whether the temporary congressional block on the OMB-originated grant policies holds, and whether NIH adopts the peer-review limits or topic restrictions.
- Whether Vertex or the Cystic Fibrosis Foundation disclose fuller spending, which would let the public share of total cost be calculated.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence50
- Adoption
- Insufficient
- Hype gap+15
- Incentives60
- Confidence50
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
In 1979 the median age of death from cystic fibrosis was 15.
- [2]
Vertex Pharmaceuticals launched Kalydeco (ivacaftor) in 2012, followed by Orkambi in 2015, Symdeko in 2018, Trikafta in 2019 and Alyftrek in 2024.
- [3]
The author states that the median survival age for a child with cystic fibrosis born today in the United States is 66 years.
- [4]
NIH funding supported more than 6,200 published research papers on the biology of cystic fibrosis in the 27 years before Kalydeco was approved in 2012.
- [5]
The author and colleagues identified US$3.2 billion in NIH funding for basic research on cystic fibrosis from 1985 to 2012.
- [6]
The author and colleagues identified approximately $940 million in NIH funding for applied research on potential cystic fibrosis drugs over the same period.
- [7]
The NIH funding complemented at least $200 million in investments from the Cystic Fibrosis Foundation for discovery or development of the drugs, as well as undisclosed spending by Vertex to develop and commercialize them.
- [8]
The author says NIH was the largest contributor to the decades of research behind the drugs and funded much of the pivotal research on the genetics and biology of the disease, and that only with this knowledge was it possible to begin searching for drugs.
- [9]
In a 2025 letter to Russell Vought and other Trump administration leaders, the Cystic Fibrosis Foundation wrote that "ensuring that the National Institutes of Health (NIH) is fully functional is critical for furthering our knowledge of the biology of CF and advancing CF therapeutic development."
- [10]
Mary Vought, the former wife of OMB director Russell Vought, stated that their daughter, who was diagnosed with cystic fibrosis, "can live likely a full life because of this miracle drug."
- [11]
FDA-approved drugs are typically based on 20 to 30 years of basic research in the lab and eight to nine years of human testing in the clinic.
- [12]
The author wrote: "Cystic fibrosis treatments are not miracles; they required decades of research funded by a combination of public and private investments."
- [13]
Some of the NIH-funded publications describe celebrated milestones in understanding CFTR, the gene that causes cystic fibrosis, or the disease process; others describe studies needed to replicate, refute or refine those advances.
- [14]
The author trained as a pediatrician in the late 1970s, when there was no treatment for cystic fibrosis itself.
- [15]
NIH basic plus applied cystic fibrosis funding identified for 1985 to 2012 is about $4.14 billion.
- [16]
If the basic-research and clinical phases ran back to back, the typical span from first basic work to approval is 28 to 39 years.
- [17]
NIH's identified total is about 21 times the Cystic Fibrosis Foundation's disclosed minimum, and because the Foundation figure is a floor, 21 is a ceiling on the ratio.
- [18]
Policies initially proposed by the Office of Management and Budget would increase political control over federal research grants, limit peer review and curtail research on certain topics.
- [19]
Congress temporarily blocked those policies, but several federal agencies, including NIH, are still pursuing portions of the agenda.
Get this ledger inside ChatGPT. Ask about any of our stories and the answer brings its figure, each claim’s verdict and the sources. Free, no account.
Sources
1 independent publisher whose own reporting we read for this story.
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Entities
- National Institutes of HealthFollow
- VertexFollow
- Cystic Fibrosis FoundationFollow
- Office of Management and BudgetFollow
- Russell VoughtFollow
- TrikaftaFollow
- The ConversationFollow